Company Announcements

Brown Advisory US Smaller Companies (BASC)

26/09/2024

Results analysis from Kepler Trust Intelligence

In the twelve months to 30/06/2024, Brown Advisory US Smaller Companies' (BASC) NAV increased by 2.8%, relative to a 10.7% rise in the sterling-adjusted Russell 2000 Total Return Index. BASC's share price rose by 5.1% over the same period, marking a slight narrowing of the discount from 14.8% to 12.8%. BASC's discount has subsequently narrowed further to c. 12%.

Factors contributing to performance included smaller companies lagging their larger US peers for the third consecutive financial year, BASC's underweight position in financials (which rallied in late 2023) and negative earnings surprises in a small number of healthcare and information technology portfolio companies.

Chair Stephen White said "After a period of dull returns from US small caps, we see a more favourable picture going forward. At the same time, we also see a return to the fore of our manager's investment style with its focus on earnings analysis, cash flow generation and balance sheet quality, rather than on speculation and momentum. We believe our portfolio is well placed to take advantage of this situation."

Kepler View

US large-caps continued to outperform in the year to 30/06/2024, with the S&P 500 delivering a total return of 25% (in US dollars), significantly above the 10% return from the Russell 2000 Total Return Index. A key driver was the perceived direction of US interest rates, with reticence from the Fed to start cutting rates weighing on the valuation of small-cap equities while investors flocked to the perceived AI exposure of the magnificent seven.

Manager Christopher Berrier believes that the weight of passive funds has also propped up lower-quality companies in the sector, which presents an opportunity for stock-pickers once the focus returns to company fundamentals. Small-cap valuations remain below historic levels and their large-cap peers, providing the opportunity to find attractively-valued companies in a broad and under-researched universe.

While recent returns have lagged the benchmark over the shorter-term, with a 6.4% rise in NAV in the three years ending 31/03/2024 compared to an 8.9% increase in the sterling-adjusted Russell 2000 Total Return Index, the team has a strong record of long-term outperformance in its open-ended US smaller companies strategy.

Sector allocation has been the main detractor to performance over the last three years, and in particular, an underweight position to the oil sector. However, stock selection in the higher-growth sectors of healthcare and information technology has been a strong contributor to returns, including Biohaven Pharmaceuticals, EVO Payments and Mimecast Limited.

It should be noted that Chris is a bottom-up stock-picker meaning that sector allocations are a function of the quality growth characteristics that he looks for. The trust's focus on companies offering durable growth, good governance and a strong 'go-to-market' position has resulted in BASC missing out on some of the more momentum-driven and speculative stocks which have driven the small-cap sector in the last financial year. However, the trust's risk-controlled approach, together with a focus on quality factors, should lead to outperformance over the longer-term.

Looking forward, BASC should be well-placed to capitalise on a more supportive macroeconomic backdrop and a return to company fundamentals over the coming year.

CLICK HERE TO READ THE FULL REPORT 

Visit Kepler Trust Intelligence for more high quality independent investment trust research.

Important information

This report has been issued by Kepler Partners LLP.  The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.  

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.